Table of Contents
ISRN Neurology
Volume 2012, Article ID 451457, 5 pages
Clinical Study

Switching and Escalating Therapy in Long-Lasting Multiple Sclerosis: Not Always Necessary

1MS Clinic, Department of Neurology, Centro Hospitalar de São João, 4200-319 Porto, Portugal
2Department of Neurology, Centro Hospitalar de Vila Nova Gaia/Espinho, 4434-502 Vila Nova de Gaia, Portugal
3Faculty of Health Sciences, University Fernando Pessoa, 4249-004 Porto, Portugal

Received 29 October 2012; Accepted 3 December 2012

Academic Editors: K. Dorovini-Zis, E. A. Joosten, T. Müller, Y. Ohyagi, Y. Sunada, and S. Weis

Copyright © 2012 Ana Teresa Carvalho and Maria José Sá. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [1 citation]

The following is the list of published articles that have cited the current article.

  • Christoph Kleinschnitz, Gabriele Niemczyk, Karin Rehberg-Weber, and Colin Wernsdörfer, “Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study,” International Journal of Molecular Sciences, vol. 16, no. 7, pp. 15271–15286, 2015. View at Publisher · View at Google Scholar